• Vaccine Name: N. meningitidis NspA Protein Vaccine
• Target Pathogen: Neisseria meningitidis
• Target Disease: Meningitis
• Vaccine Ontology ID: VO_0004013
• Type: Subunit vaccine
• Status: Research
• NspA from N. meningitidis MC58 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001263
  • Description: QuilA (CedarLane Laboratories, Hornby, Ontario, Canada) (Martin et al., 1997).
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Vaccination Protocol: Groups of mice were injected three times at 3-wk intervals with 10 or 20 μg of affinity-purified NspA recombinant protein and 25 μg of QuilA (CedarLane Laboratories, Hornby, Ontario, Canada) as the adjuvant. Control mice were injected with either 20 μg of BSA (Sigma), concentrated E. coli BL21(DE3) supernatant, or PBS. 2 wk after the third injection the mice were used for the protection experiments (Martin et al., 1997).
• Challenge Protocol: For inoculation of mice, meningococci were removed from the chocolate agar plates after ∼20 h of incubation and suspended in PBS and injected into mice (Martin et al., 1997).
• Efficacy: 80% of the mice immunized with three injections of either 10 or 20 μg of purified recombinant meningococcal NspA protein survived the bacterial challenge comparatively to 0 to 20% in the control groups. Survivors at 72 h did not succumb during an additional two weeks of observation. The mice in the control group injected with concentrated E. coli culture supernatant were not protected against the bacterial challenge indicating that the components present in the culture media and other E. coli antigens that might be present in small amounts after purification do not contribute to the observed protection against N. meningitidis (Martin et al., 1997).